What was the major announcement from Radiopharm Theranostics (ASX:RAD) at AACR 2026?

Radiopharm Theranostics announced positive initial findings from its Phase 1 "HEAT" first-in-human clinical trial for 177Lu-RAD202. The data, presented at the American Association for Cancer Research (AACR) meeting, showed that the therapy successfully targeted HER2-positive solid tumours with a favourable safety profile.

How did patients respond to the 177Lu-RAD202 therapy in the initial trial?

In a cohort of three patients with heavily pre-treated metastatic breast and urothelial cancers, 177Lu-RAD202 showed meaningful tumour uptake at the lowest dose of 30 mCi. This uptake was particularly notable in breast cancer lesions.

What are the key safety findings for Radiopharm Theranostics (ASX:RAD)?

The trial reported no dose-limiting toxicities or treatment discontinuations due to adverse events, which is a major "green flag" for early-stage biotech. Patients experienced only mild Grade 1–2 treatment-emergent side effects.

What does the "dose escalation" phase mean for RAD shareholders?

Following the successful safety data at 30 mCi, the Data Safety and Monitoring Committee approved jumping to a third cohort at a much higher dose of 130 mCi. For investors, this rapid escalation is significant because it allows the company to test for higher "antitumour activity" (efficacy) sooner.

Is Radiopharm Theranostics (ASX:RAD) currently profitable?

No, Radiopharm Theranostics is a clinical-stage biopharmaceutical company and is not yet profitable. As of this report, the company’s share price was $0.021, reflecting its status as a high-risk, high-reward speculative biotech.

What is the investment thesis for Radiopharm Theranostics after this news?

The bull case is that RAD is successfully entering the "radiopharmaceutical" space, a high-growth sector of oncology that has seen significant M&A activity recently. By proving 177Lu-RAD202 is safe in humans, the company de-risks the asset and moves closer to treating high-unmet-need HER2+ cancers. The bear case remains the long road to FDA approval and the high cash-burn rate typical of Phase 1/2 clinical trials.

Radiopharm Theranostics reports positive Phase 1 trial results

Written by Brie CarterPublished Apr. 20 2026Last Updated Apr. 20 2026

Radiopharm Theranostics (ASX:RAD) has achieved a clinical milestone, unveiling initial data from its Phase 1 "HEAT" first-in-human clinical trial.

Presented at the American Association for Cancer Research annual meeting 2026 in San Diego, the findings evaluate 177Lu-RAD202, a pioneering HER2-targeted radiopharmaceutical therapy designed to treat advanced solid tumours.

The trial’s initial cohort involved three patients with heavily pre-treated metastatic breast and urothelial cancers.

Results from the lowest dose level of 30 mCi demonstrated meaningful tumour uptake, particularly within breast cancer lesions.

The therapy was generally well tolerated; researchers reported only Grade 1–2 treatment-emergent adverse events, with no dose-limiting toxicities or treatment discontinuations observed.

Furthermore, organ-level absorbed radiation doses remained within clinically acceptable ranges, confirming a favourable safety profile for the novel compound.

Dr Dimitris Voliotis, Chief Medical Officer of Radiopharm Theranostics, described the results as an important early milestone for the company’s HER2-targeted programme.

He emphasised that the observed dosimetry supports the ongoing expansion of the study.

The Data Safety and Monitoring Committee has recently approved advancing the trial to a third cohort at a significantly higher dose of 130 mCi.

As dose escalation continues, the company anticipates observing increased antitumour activity, potentially offering a new lifeline for patients with high unmet medical needs who have exhausted traditional metastatic therapies.

At the time of reporting, Radiopharm Theranostics’ share price was $0.021.